CGT
-
一款CAR-T 换 18%股份，信达生物的取舍
关注药时代，一起洞察行业，共创未来！
-
CAR-T Black Box Warning Controversy Again？
DrugTimes will follow this crucial matter and report timely
-
【ASCO Highlights】China-made First-in-Class Claudin 18.2 CAR-T Therapy Shows Promising Phase I Results!
Follow Drug Times to grasp valuable industry information at the first moment
